

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ :

A61M 15/00

A1

(11) International Publication Number:

WO 93/098

(43) International Publication Date:

93/0832
27 May 1993 (27.0:

(21) International Application Number: PCT/US92/09505

(22) International Filing Date: 6 November 1992 (06.11.92)

(30) Priority data:

9123953.3

12 November 1991 (12.11.91) GB

(71) Applicant (for all designated States except US): MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HODSON, Peter, D. [GB/GB]; 5 Kingmead Avenue, Trowell Park, Trowell, Notts NG9 3QX (GB).

(74) Agents: REEDICH, Douglas, E. et al.; Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).


(81) Designated States: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MN, MW, NL, NO, PL, RO, RU, SD, SE, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending claims and to be republished in the event of the receipt of amendments.

(54) Title: INHALATION DEVICE



(57) Abstract

A dry powder inhaler having one or more deagglomeration channels through which an air stream containing entrained medicament particles passes. Each channel has a substantially constant cross-sectional area and a bend having a radius of curvature of no greater than 10 mm.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SU	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

INHALATION DEVICE

Field of the Invention

This invention relates to dry powder inhalation
5 devices.

Description of the Related Art

Asthma and other respiratory diseases have long
been treated by inhalation of medicament. For many
10 years, the two most widely used and convenient choices
of treatment have been inhalation of medicament from a
drug solution or suspension in an aerosol propellant
from a metered dose pressurized inhaler, or inhalation
of powdered drug, generally admixed with a powdered
15 excipient, from a dry powder inhaler. With growing
concern being voiced over the strong link between
depletion of the earth's ozone layer and
chlorofluorocarbon emissions, the use of these
materials as aerosol propellants in pressurized
20 inhalers is being questioned and interest in dry powder
systems has been stimulated.

Most single and multiple dose dry powder inhalers
use either individual premeasured doses of medicament
which are inserted into a dispensing chamber prior to
25 use, or they incorporate a bulk powder reservoir from
which successive quantities of medicament are
transferred to the dispensing chamber. Such inhalers
generally comprise an air passage leading from the
dispensing chamber which terminates in a patient port
30 adapted to be inserted into the mouth or nasal passage
of the patient. Patient inhalation at the patient port
generates an air stream through the dispensing chamber
which carries particles of medicament into the lungs of
the patient.

35 Examples of such dry powder inhalers are disclosed
in U.S. Patent Nos. 2,587,215, 3,669,113, 3,948,264,
3,971,377, 4,046,146, 4,098,273, 4,137,914, 4,147,166,

4,192,309, 4,240,418, 4,674,491, 4,846,168; British Patent Nos. 1,118,341, 1,268,051, 1,526,303, 2,041,763, 2,061,735, 2,165,159, and 2,191,718; European Patent No. 237507 and International Patent No. WO 90/07351.

5 A problem common to many dry powder systems is the tendency of the powdered medicament to agglomerate. Agglomeration is caused by individual particles of medicament adhering together in a semi-rigid mass, and
10 to separate and entrain drug particles into the air stream. If the patient is unable to provide sufficient inspiratory effort the extent of drug penetration into the lower airways of the lung will be reduced. Larger agglomerated drug particles ($> 10 \mu\text{m}$) which result from
15 inefficient aerosolization are not stably entrained into the patient's air stream and prematurely deposit in the mouth or throat region which may lead to unwanted systemic side effects, especially when potent drugs are administered.

20 It is desirable to utilize the action of the patient's breathing both to deagglomerate and aerosolize the powdered drug, thereby overcoming the coordination problems necessary to synchronize inhalation with means for medicament aerosolization.
25 The efficiency of powder aerosolization, however, is solely determined by the patient's inspiratory effort. Consequently, a patient having difficulty breathing, e.g., during an asthma attack, may possess insufficient inspiratory effort to deagglomerate and aerosolize the
30 medicament and inhale the required dose at a time when the patient has the greatest need for the drug.

Many inhalation devices have attempted to solve the problems attributable to powder agglomeration by incorporating into the device deagglomeration and
35 aerosolization means, e.g., a battery-powered solenoid buzzer, which cause or assist deagglomeration and aerosolization of the powdered medicament by breaking

up particle agglomerates entirely independent of the patient's inspiratory effort. Examples of such devices are disclosed in, e.g., U.S. Patent Nos. 3,948,264, 3,971,377, and 4,147,166. The device may be made fully
5 independent of the patient by incorporating a breath actuation mechanism responsive to respiratory flow, which is able to synchronize medicament release with patient inhalation. An example of such a device is disclosed in our copending International Patent
10 Application No. 90/00670 filed on 30th April 1990.

Dry powder inhalers are also known which incorporate features to assist the break up of particle agglomerates in the powder laden air stream.

For example, British Patent No. 1,268,051 and U.S.
15 Patent No. 3,669,113 disclose dry powder inhalers in which a premetered dose of powdered medicament is contained in a capsule and the airflow past the capsule is increased in velocity by means of a constriction in the air passage. British Patent No. 2,165,159
20 discloses a dry powder inhaler with a storage chamber for powdered drug comprising a constricted region in the air passage in the mouthpiece region.

British Patent Nos. 1,478,138, 1,526,303 and 2,061,735 and U.S. Patent Nos. 3,948,264, 4,046,146,
25 4,137,914, 4,240,418, and 4,846,168 disclose dry powder inhalers having an angled mouthpiece which forces the powder laden air stream to pass round a bend.

U.S. Patent Nos. 2,587,215 and 4,674,491 and International Patent No. WO 90/07351 disclose dry
30 powder inhalers in which the powder laden air stream is forced to take a fairly tortuous path prior to exiting the mouthpieces of the devices. British Patent Nos. 1,118,341 and 2,191,718 and European Patent No. 237507 disclose dry powder inhalers in which the particle
35 laden airstream is forced to pass round interdigitated baffles or similar in the mouthpiece region.

Summary of the Invention

It has now been found that by providing an air passage for carrying a powder laden airstream with one or more deagglomeration channels of defined

5 configuration, it is possible to impart sufficient shear forces to particle agglomerates entrained therein to separate them into smaller particles which are more readily inhaled by the patient.

Therefore, according to the present invention

10 there is provided a dry powder inhaler for dispensing powdered medicament comprising a housing defining a chamber for receiving a dose of powdered medicament, one or more air inlets, and a patient port adapted for insertion into the mouth or nasal passage of the

15 patient, constructed and arranged to provide an air passage extending from the air inlet(s) through the chamber to the patient port so that patient inhalation at the patient port generates an airflow through the inhaler which entrains particles of medicament from the

20 chamber for inhalation by the patient, and in which the air passage is provided with one or more deagglomeration channels between the chamber and patient through which the airstream with entrained medicament must pass, each channel having a

25 substantially constant cross-sectional profile with a cross-sectional area no greater than 40 mm^2 , a first opening communicating with the dispensing chamber, a second opening communicating with the patient port and intermediate of said first and second openings either:

30 (i) a single bend of from 70° to 160° wherein the minimum radius of curvature of the center of the bend is no greater than 10 mm, or

(ii) two or more bends each of from 35° to 200° , wherein the minimum radius of curvature of the center

35 of the bends is no greater than 10 mm.

Detailed Description of the Invention

The present invention utilizes one or more shaped and dimensioned channels to confine the powder carrying airstream leaving the dispensing chamber, thereby
5 imparting shear and wall friction forces to the particles. These forces are particularly efficient at breaking up particle agglomerates into smaller particles which are capable of being inhaled into the human lung. The cross-sectional profile and dimensions
10 of the deagglomeration channel(s) are selected so as to maximize delivery of respirable sized particles (2 to 5 μm) over the whole range of likely inhalation rates, while minimizing factors such as drug deposition. It has been found that a channel of substantially constant
15 cross-sectional profile of up to 40 mm^2 (inclusive), imparts enough shear and wall friction forces to promote the deagglomeration of entrained powder agglomerates.

The final choice of cross-sectional profile will
20 depend on factors such as the starting state of the powder, the required degree of deagglomeration, the pressure drop desired at a particular flow rate and the space available inside the device. The deagglomeration channel(s) may be formed with any suitable profile with
25 the important proviso that the cross-sectional area perpendicular to the longitudinal axis (airflow direction) of the channel is no greater than 40 mm^2 . It is preferred to avoid shapes with abrupt or angular features which tend to promote excessive powder
30 deposition. Larger channels having a cross-sectional area greater than 40 mm^2 tend not to cause adequate deagglomeration of powder. Smaller channels, that is, having a cross-sectional area of less than 40 mm^2 aid deagglomeration by increasing air velocities and
35 turbulence, but they also tend to give rise to greater pressure drops for a given airflow rate, resulting in

greater powder deposition and therefore a net reduction in the quantity of respirable powder. Thus, it is preferred that the cross-sectional area of the channel(s) is not greater than 30 mm² and more preferably in the range 15 to 25 mm².

It is important to ensure that the pressure drop which the patient needs to attain to provide a suitable airflow rate for inhalation of the medicament, typically 30 to 60 liters/minute, is not excessively uncomfortable. A pressure drop of, e.g., ≤ 400 mm water is suitable.

Each channel incorporates either a single bend of from 70 to 160° or two or more bends, each of from 35 to 180° with the proviso that the radius of curvature of the center of the bend or bends is no greater than 10 mm. The radius of curvature of the center of the bend(s) is preferably no greater than 5 mm and more preferably from 1.5 to 5 mm.

When the channel(s) is formed with two or more bends, then the second and subsequent bends may be formed in the same or in different planes and be of the same or opposing handedness to that preceding it. Preferably, the channel(s) is provided with two bends, with the second bend being of opposing or reverse handedness to that of the first, thereby forming an 'S' bend. Where the inhaler comprises a plurality of deagglomeration channels they are normally of a similar or identical configuration.

The channel(s) preferably have a uniform cross-sectional profile throughout their length. However, variations in the cross-sectional profile are permitted providing they do not substantially alter the airflow through the channel(s).

Although the deagglomeration channel(s) may be interposed at any suitable point in the air passage between the dispensing chamber and patient port, it is

preferred to form the channel(s) in or immediately adjacent to the patient port to avoid excessive pressure drops. Therefore, the space available inside the patient port region of the inhaler is an important factor determining the configuration of the deagglomeration channel(s). This space may be limited in an inhaler incorporating a breath actuation mechanism in the form of a movable vane responsive to patient inspiration. Ideally, the deagglomeration channel(s) should occupy a volume of around 10 x 15 x 15 mm.

The overall path length provided by the deagglomeration channel(s), that is, the average distance travelled by the powder laden airstream between the first and second openings, is generally no greater than 4 cm and preferably no greater than 3 cm to avoid excessive powder deposition and pressure drop. The internal surface of the channel(s) may be smooth or it may be patterned, e.g., with grooves angled relative to the direction of the airflow to induce turbulence.

The advantages of the present invention may be summarized as follows:

(a) good deagglomeration performance with a high respirable fraction (typically >35% of the total weight of the powder) and a high respirable dose (e.g., >75 μ g);

(b) acceptable pressure drop (e.g., at 60 liters/minute);

(c) small space requirements and ready compatibility with breath actuation mechanisms; and

(d) the deagglomeration channel(s) acts as a guard to reduce the chance of any fragments of broken capsules (in capsule dry powder inhalers) or other extraneous matter from being inadvertently inhaled by the patient.

The invention will now be described by way of example with reference to the accompanying drawings in which:

Figure 1 is a longitudinal section through a dry powder inhaler of the present invention;

Figure 2 is an enlarged view of a portion of the mouthpiece of the dry powder inhaler of Figure 1;

Figure 3 is a sectional view along the line A-A of the mouthpiece of the dry powder inhaler of Figure 1, and

Figures 4 and 5 are sectional views of alternative arrangements of mouthpiece suitable for use with the inhaler of Figure 1.

Figure 1 depicts a dry powder inhaler of the type disclosed in our copending International Patent Application No. GB 90/00670 filed on 30th April 1990.

The device (2) comprises a housing (4) defining a dispensing chamber (6) in communication with a patient port in the form of a mouthpiece (8). A cover (10) is movable about pivot point (12) between a closed position (not shown), which protects the contents of the device from the ingress of moisture and other contaminants, and an open, dispensing position as shown.

The housing (4) contains an elongate carrier (14) which is initially wound on a supply spool (16). From the supply spool (16), the elongate carrier (14) passes round two guide rollers (18 and 20) to a take up spool (22). An area (24) of the elongate carrier (14) between the two guide rollers (18 and 20) is exposed to the dispensing chamber (6). When the device (2) is actuated (as shown), powdered medicament (26) is released from the elongate carrier (14) and entrained in the patient's inspiratory airflow.

The device (2) is operated by the patient opening the cover (10) and inhaling through the mouthpiece (8). This activates three mechanisms, namely: a driving

mechanism for advancing the elongate carrier (14); an
impaction mechanism which causes the exposed area (24)
of the elongate carrier (14) to be impacted, thereby
ensuring the release of powdered medicament into the
5 patient's airstream, and a trigger mechanism which
ensures that the energy stored in the cocked impaction
mechanism is not released until inhalation is detected.

The device (2) comprises means to facilitate the
release of the powdered medicament (26) from the
10 elongate carrier (14) in the form of an impaction
mechanism (28). After the patient has begun to inhale
through the mouthpiece (8), thereby releasing the
triggering mechanism, the area (24) of the elongate
carrier (14) exposed to the dispensing chamber (6) is
15 struck by a hammer (30) driven by a powerful spring
(not shown) to assist the release of medicament (26)
into the developing airstream. When cocked, and prior
to patient inhalation through the device (2), the
hammer (30) is held clear of the elongate carrier (14)
20 by a catch (not shown) which engages the hammer (30)
until such time as the trigger mechanism senses patient
inhalation. A reset member (not shown) is provided on
the cover (10) which, on closure of the device (2),
engages and returns the hammer (30) to its original
25 position where it is reengaged by the catch.

The trigger mechanism comprises a movable vane
(32) which is pivotally mounted in the mouthpiece (8)
at (34) so as to be displaceable when an airflow is
generated through the device (2) from the exterior
30 atmosphere to the mouthpiece (8) via air vents (36) (as
shown). Displacement of the vane (32) in response to
patient inhalation produces an interaction with the
catch of the impaction means (28) to release the hammer
(30). The vane (32) ensures unidirectional flow of air
35 from the exterior atmosphere to the mouthpiece (8) by
being displaceable in the forward direction only.

- 10 -

Movement in the reverse direction upon patient exhalation is prevented by stop (38).

The drive mechanism comprises an integral belt (40), the purpose of which is to keep the rotational movement of the supply and take up spools (16 and 22) in precisely the correct relationship to each other and to a control roller (42) regardless of the proportion of the elongate carrier (14) which has been passed between spools. This objective is achieved by the drive belt (40) being in frictional contact with the control roller (42) and with the rear surface of the elongate carrier (14) on each of the spools (16 and 22). In order to achieve the necessary arc of contact between the drive belt (40) and elongate carrier (14) on the spools (16 and 22), the device additionally comprises guide rollers (44 and 46). The elongate carrier (14) is advanced by driving the control roller (42) to cause rotational movement of each spool (16 and 22). The control roller (42) is driven by the act of opening the cover (10) of the device (2) after it has been used by the patient. A drive gear (48) mounted on the pivot (12) of the cover (10) is rotated as the cover (10) is opened and closed. Unidirectional (clockwise) rotation of the control roller (42) is ensured by the provision of a ratchet mechanism (50) which prevents 'wrong-way' rotation when the cover (10) is closed. In this manner, the sequential advancement of unexposed areas (24) of the carrier (14) is coordinated with the simple act of opening and closing the cover (10) of the device (2).

The mouthpiece (8) is provided with a single integrally formed deagglomeration channel (52) which effects the break up of large particle agglomerates released from the carrier (14) into smaller particles of a more respirable size. The deagglomeration channel (52) comprises a first opening (54) communicating with the dispensing chamber (6), a second opening (56)

- 11 -

communicating via the mouthpiece with the exterior atmosphere and disposed along its length a first bend (58) of about 150° and a second bend (60) of about 135° . Referring by way of example to Figure 2, which depicts an enlarged view of the first bend (58) of the deagglomeration channel (52), the minimum radius of curvature 'r' of the center of each bend (58 and 60) is no greater than 10 mm, preferably no greater than 5 mm and more preferably between 1.5 and 5 mm (inclusive).

10 It will be appreciated that each bend may not be in the form of a single arc of a circle but may follow a path comprising two or more arcs from circles of different radii conjoined which may include short linear portions. Thus, a bend may follow any desired curve, sinusoidal, parabolic, hyperbolic, etc., providing the other essential parameters of the bend are present.

15 The value of the minimum radius of curvature of the arcs constituting a bend must not be greater than 10 mm. The radius is measured to the centerline of the bend, i.e., mid point between the sidewalls of the channel in the plane of the bend, as shown in Figure 2.

The deagglomeration channel (52) works by constricting the flow of the powder laden airstream from the dispensing chamber, thereby imparting shear and wall friction forces to the particles entrained therein. It is these forces which are responsible for the breakup of the particle agglomerates. Although the deagglomeration channel may have any suitable cross-section which does not promote excessive powder deposition, three particularly preferred profiles are illustrated in Figures 3, 4, and 5. In each case, the total cross-sectional area of the channel when measured at a point perpendicular to the longitudinal axis of the channel should not exceed 40 mm^2 and is preferably

30 no more than 30 mm^2 .

- 12 -

Referring to Figure 3, the deagglomerator channel is formed with a slot or bar-shaped profile (62) typically having a length (1) of from 8 to 40 mm, preferably 8 to 30 mm and more preferably 8 to 16 mm and a width (w) of from 1 to 5 mm, preferably 1 to 2.5 mm and more preferably 1.2 to 1.6 mm. A slot of 14 mm length with a width of 1.5 mm (total cross-section 21 mm^2) was found to release doses of $180 \mu\text{m}$, from an inhaler of the type shown in Figure 1 with about $70 \mu\text{m}$ (39%) of the particles having a size in the range of from 2 to $5 \mu\text{m}$ (as recorded using a twin stage impinger at a flow rate of 60 l/min).

Figure 4 shows a modification to the deagglomeration channel of Figure 3, in which an opening (54) of greater dimension is formed along the center of the channel in order to reduce the pressure drop experienced by the patient, particularly at high inhalation rates, by providing a central, lower resistance, less turbulent bypass route for air at high flow rates. However, the majority of the powder aerosol still passes close to the walls of the channel where the deagglomerating forces are at their strongest. Typical values for 'l', 'w', and 'd' are 14, 1.5, and 4 mm respectively.

Figure 5 illustrates a further arrangement of mouthpiece where the single slot or modified slot of Figures 3 and 4 have been replaced by three equi-size channels of circular cross-section (66). The diameter 'd' of each channel is generally in the range of from 2 to 7 mm, preferably 2 to 5 mm with a typical value of about 3 mm.

- 13 -

Claims:

1. A dry powder inhaler for dispensing powdered medicament comprising a housing defining a chamber for
5 receiving a dose of powdered medicament, one or more air inlets, and a patient port adapted for insertion into the mouth or nasal passage of the patient, constructed and arranged to provide an air passage extending from the air inlet(s) through the chamber to
10 the patient port so that patient inhalation at the patient port generates an airstream through the inhaler which entrains particles of medicament from the chamber for inhalation by the patient, characterized in that the air passage is provided with one or more
15 deagglomeration channels between the chamber and patient port through which the airstream with entrained medicament must pass, each channel having a substantially constant cross-sectional profile with a cross-sectional area no greater than 40 mm^2 , a first
20 opening communicating with the dispensing chamber, a second opening communicating with the patient port and intermediate of said first and second openings either:
 - (i) a single bend of from 70 to 160° wherein the minimum radius of curvature of the center of the bend
25 is no greater than 10 mm , or
 - (ii) two or more bends each of 35 to 200° , wherein the minimum radius of curvature of the center of the bends is no greater than 10 mm .
- 30 2. A dry powder inhaler as claimed in Claim 1 in which the deagglomeration channel(s) has a cross-sectional area no greater than 30 mm^2 .
3. A dry powder inhaler as claimed in Claim 1 in
35 which the deagglomeration channel(s) has a cross-sectional area of from 15 to 25 mm^2 .

- 14 -

4. A dry powder inhaler as claimed in Claim 1 in which the minimum radius of curvature of the center of the bend(s) is no greater than 5 mm.

5 5. A dry powder inhaler as claimed in Claim 4 in which the minimum radius of curvature of the center of the bend(s) is from 1.5 to 5 mm.

6. A dry powder inhaler as claimed in Claim 1 in
10 which the deagglomeration channel(s) is formed with two or more bends, the second and subsequent bends being of opposite-handedness to that preceding it.

7. A dry powder inhaler as claimed in Claim 1 in
15 which the deagglomeration channel(s) is formed with a first bend of about 150° and a second bend of about 135°.

8. A dry powder inhaler as claimed in Claim 1 in
20 which the overall path length between the first and second openings of the deagglomeration channel(s) is no greater than 4 cm.

9. A dry powder inhaler as claimed in Claim 1 in
25 which the deagglomeration channel(s) has a slot shaped profile of length 8 to 30 mm and width 1 to 2.5 mm.



10. A dry powder inhaler as claimed in Claim 1 in which the deagglomeration channel(s) has a slot shaped
30 profile of length 8 to 16 mm and width 1.2 to 1.6 mm.




11. A dry powder inhaler as claimed in Claim 9 in which the slot has a central aperture to provide a route for air at high(er) flow rates.

- 15 -

12. A dry powder inhaler as claimed in Claim 1 in which the deagglomeration channel(s) has a circular cross-section of diameter 2 to 7 mm.

5 13. A dry powder inhaler as claimed in Claim 1 in which the deagglomeration channel(s) are formed in or immediately adjacent the patient port.

**FIG. 2**



PCT/US 92/09505.

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61M 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO, A1, 9208509 (MINNESOTA MINING AND MANUFACTURING COMPANY), 29 May 1992 (29.05.92), figures 11,12	1-10,12,13
Y,P	figures 11,12	11
Y	GB, A, 1118341 (FISONS PHARMACEUTICALS LIMITED), 3 July 1968 (03.07.68), figure 4	11
A	GB, A, 2041763 (PAOLO CHIESI ET AL), 17 Sept 1980 (17.09.80), figure 2, abstract	1-13

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

3 March 1993

Date of mailing of the international search report

25.03.93

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL-2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Telex 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Lena Nilsson

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim ?
A	GB, A, 2165159 (ORION-YHTYMA OY), 9 April 1986 (09.04.86), figure 2, abstract --	1-13
A	EP, A1, 0237507 (AKTIEBOLAGET DRACO), 16 Sept 1987 (16.09.87), figure 1, abstract -----	1-13

INTERNATIONAL SEARCH REPORT
information on patent family members

SA 1225

29/01/93

International application No.

PCT/US 92/09505

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9208509	29/05/92	AU-A- 8873391	11/06/92
GB-A- 1118341	03/07/68	NONE	
GB-A- 2041763	17/09/80	FR-A,B- 2447725	29/08/80
GB-A- 2165159	09/04/86	CH-A,B- 666823	31/08/88
		DE-A- 3535561	22/05/86
		JP-A- 61090674	08/05/86
		SE-A- 8504541	05/04/86
EP-A1- 0237507	16/09/87	AU-B- 601400	13/09/90
		AU-A- 6960487	10/09/87
		CA-A- 1276848	27/11/90
		DE-A- 3775433	06/02/92
		JP-A- 62221366	29/09/87
		SE-B,C- 453566	15/02/88
		SE-A- 8601060	08/09/87
		US-A- 4907583	13/03/90
		ZA-A- 8701346	07/09/87